Are GLP-1R agonists the long-sought-after panacea for obesity?

Editorial Material Endocrinology & Metabolism

What's preventing us from curbing the obesity crisis?

[Anonymous]

LANCET DIABETES & ENDOCRINOLOGY (2022)

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adolescents with Obesity

Daniel Weghuber et al.

Summary: This double-blind, randomized, placebo-controlled trial found that once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone among adolescents with obesity.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff et al.

Summary: In this 72-week trial in participants with obesity, once-weekly doses of 5 mg, 10 mg, or 15 mg of tirzepatide provided substantial and sustained reductions in body weight, and improvements in cardiometabolic measures were also observed.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental